Genetically Weakened Malaria Vaccine Protected 13 of 15 Volunteers Against a Mismatched Strain in Early Seattle Trial
An experimental malaria vaccine made from a genetically weakened parasite protected 13 of 15 healthy volunteers from infection when they were deliberately exposed to malaria 12 to 16 weeks after their last dose, an efficacy of 87%. Researchers presented …